ELISA单试剂不合格献血者归队可行性分析
|
摘要
目的了解合肥地区既往HBsAg、抗-HCV、HIV抗原/抗体、抗-TP中ELISA单试剂反应性或灰区,并被血站信息管理系统屏蔽的献血者召回归队的可行性。方法对本站2013年11月—2016年8月间共268名屏蔽>6个月、既往ELISA 4项单试剂反应性或灰区现要求归队的献血者先检测ELISA 4项(HBsAg、抗-HCV、HIV抗原/抗体、抗-TP)和HBV、HCV、HIV 3项病毒核酸检测;全部合格后,针对屏蔽项目加做第3家ELISA试剂检测和相应确证试验(HBsAg:中和试验;抗-HCV:RIBA;抗-HIV:WB;抗-TP:TPPA),对因HBsAg屏蔽的献血者补充检测抗-HBc,均合格者允许归队。结果 268名献血者按归队流程检测后,共有132名献血者可以回归献血者队伍,总合格率为49.25%(132/268)。结论通过归队流程确实能使近一半的ELISA单试剂不合格献血者归队,保留了一部分血液资源,但这一比例远低于普通献血者的合格比例,血站应慎重对待归队工作,因归队策略的不当选择而召回献血者献血可能会存在安全输血风险。
Objective To understand the feasibility of the recall of HBsAg,anti-HCV, HIV-Ag/Ab,anti-TP,and free of single reagent in the area of Hefei. Methods From November 2013 to August 2016,a total of 268 be shielded more than six months, ELISA past four single reagent reactive or grey area has required return donors to detect from four ELISA(HBsAg, HCV-Ab, HIV Ag/Ab, TP-Ab) and HBV, HCV, HIV three nucleic acid detection.After all qualified, a third ELISA test and the corresponding confirmed test(HBsAg: neutralization test; HCV-Ab: RIBA; HIV-Ab: WB; TP-Ab: TPPA), and HBcAb is added to the blood donors who are screened by HBsAg. All qualified will be allowed to return. Results After 268 blood donors were tested by the returning team, a total of 132 blood donors were returned to the blood donors, the total qualified rate was 49.25%(132/268). Conclusion Through the return process can actually make nearly half of the single ELISA reagent unqualified return blood donors, retained some blood resources, but the proportion is far lower than the average qualified rate of blood donors, blood stations should be treated with caution for work, because the return policy of improper selection and recall blood supply may exist safety risk of blood transfusion.
Objective To understand the feasibility of the recall of HBsAg,anti-HCV, HIV-Ag/Ab,anti-TP,and free of single reagent in the area of Hefei. Methods From November 2013 to August 2016,a total of 268 be shielded more than six months, ELISA past four single reagent reactive or grey area has required return donors to detect from four ELISA(HBsAg, HCV-Ab, HIV Ag/Ab, TP-Ab) and HBV, HCV, HIV three nucleic acid detection.After all qualified, a third ELISA test and the corresponding confirmed test(HBsAg: neutralization test; HCV-Ab: RIBA; HIV-Ab: WB; TP-Ab: TPPA), and HBcAb is added to the blood donors who are screened by HBsAg. All qualified will be allowed to return. Results After 268 blood donors were tested by the returning team, a total of 132 blood donors were returned to the blood donors, the total qualified rate was 49.25%(132/268). Conclusion Through the return process can actually make nearly half of the single ELISA reagent unqualified return blood donors, retained some blood resources, but the proportion is far lower than the average qualified rate of blood donors, blood stations should be treated with caution for work, because the return policy of improper selection and recall blood supply may exist safety risk of blood transfusion.
引文
[1] 安徽省卫生计生委. 安徽省献血者归队指导原则.2013.
[2] 李雪群,钟展华. 抗-HIV单试剂反应性献血者归队可行性的调查分析.实验与检验医学,2015,33(2):246-247.
[3] 武丽娟. 反应性献血者屏蔽与归队的探讨.临床输血与检验,2015,17(2):153-155.
[4] 庞栋,张翔,申卫东,等. 南宁市无偿献血者归队策略及影响因素.中国输血杂志,2015,28(5):571-573.
[5] 孙庶丽,刘勤晓,李杰. 对ELISA四项弱反应性献血者的追踪检测.中国实用医药,2013,32(8):18-19.
[6] 李玉笑,汪传喜,肖韶英,等. 暂时屏蔽的5项血清学指标不合格献血者追踪检测结果分析.中国输血杂志,2011,24(11):964-965.
[7] David Juhl,Jürgen Luhm, Siegfried G?rg, et al. Evaluation of algorithms for the diagnostic assessment and the reentry of blood donors who tested reactive for antibodies against hepatitis B core antigen. Transfusion,2011,51:1477-1485.
[2] 李雪群,钟展华. 抗-HIV单试剂反应性献血者归队可行性的调查分析.实验与检验医学,2015,33(2):246-247.
[3] 武丽娟. 反应性献血者屏蔽与归队的探讨.临床输血与检验,2015,17(2):153-155.
[4] 庞栋,张翔,申卫东,等. 南宁市无偿献血者归队策略及影响因素.中国输血杂志,2015,28(5):571-573.
[5] 孙庶丽,刘勤晓,李杰. 对ELISA四项弱反应性献血者的追踪检测.中国实用医药,2013,32(8):18-19.
[6] 李玉笑,汪传喜,肖韶英,等. 暂时屏蔽的5项血清学指标不合格献血者追踪检测结果分析.中国输血杂志,2011,24(11):964-965.
[7] David Juhl,Jürgen Luhm, Siegfried G?rg, et al. Evaluation of algorithms for the diagnostic assessment and the reentry of blood donors who tested reactive for antibodies against hepatitis B core antigen. Transfusion,2011,51:1477-1485.